Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effectiveness and safety of combining inavolisib with a cyclin-dependent kinase 4 and 6 inhibitor CDK46i and letrozole compared to placebo with CDK46i and letrozole. This study focuses on adults with endocrine-sensitive PIK3CA-mutated hormone receptor-positive, HER2-negative advanced breast cancer. The trial is a phase III, randomized, double-blind, placebo-controlled study aiming to improve first-line treatment options for this condition. Participants will be randomly assigned to receive either oral inavolisib once daily alongside letrozole and a CDK46 inhibitor or a matching placebo with letrozole and CDK46 inhibitor. The CDK46 inhibitor is given on either days 1-21 or days 1-28 of each 28-day treatment cycle. Both groups will follow this treatment regimen throughout the study period. During the trial, participants will be monitored regularly to assess progression-free survival, overall survival, and various measures of treatment response and quality of life, including pain and physical function. Safety will be closely tracked by recording adverse events and treatment-related symptoms using patient-reported outcomes. The study may last up to seven years, including long-term follow-up to evaluate the effects of the treatments over time.
Actively Recruiting
Researchers are evaluating treatments for patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated breast cancer that is locally advanced or metastatic. This phase III, global, randomized, open-label study compares the effectiveness and safety of inavolisib combined with fulvestrant versus alpelisib combined with fulvestrant. Participants have experienced disease progression during or after therapy with cyclin dependent kinase 46 inhibitors combined with endocrine therapy. Participants receive study drugs in repeated 28-day cycles. Inavolisib is taken orally once daily at 9 mg on days 1 to 28 of each cycle, while fulvestrant is administered at 500 mg on days 1 and 15 of the first cycle and day 1 of subsequent cycles. The comparator group receives alpelisib at 300 mg orally once daily plus fulvestrant on the same schedule. A substudy evaluates the effect of inavolisib plus fulvestrant on the metabolism of certain enzyme substrates by administering midazolam, omeprazole, and bupropion on specified days within the first cycle. Participants undergo regular assessments including tumor evaluations per RECIST criteria, blood tests, and monitoring of drug levels. The primary outcome measures progression-free survival assessed by independent review up to approximately 64 months. Secondary outcomes include overall survival, response rates, quality of life, and safety events monitored up to about 85 months. The study includes frequent visits during treatment cycles and follow-ups to evaluate side effects and long-term outcomes.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of EIK1001 combined with Pembrolizumab compared to a placebo plus Pembrolizumab as the first treatment for patients with advanced melanoma. This is a multicenter, randomized, double-blind phase 23 trial that includes dose optimization and expansion parts to assess these therapies. The trial is sponsored by Eikon Therapeutics and targets patients eligible for standard Pembrolizumab therapy. Participants are randomly assigned to one of three groups one receiving a placebo with Pembrolizumab, another receiving a selected dose of EIK1001 plus Pembrolizumab, and a third receiving a different dose of EIK1001 plus Pembrolizumab. EIK1001 is a drug that activates specific immune receptors, and Pembrolizumab is an immune checkpoint inhibitor. The study includes dose optimization in the early phase and expands to larger groups for further evaluation. During the study, participants will undergo regular assessments including imaging scans to measure tumor response, blood tests to monitor organ function, and evaluations of any side effects. Researchers will measure outcomes such as progression-free survival, overall survival, and objective tumor response over a period of up to five years. Safety and adverse events will be closely monitored, particularly during the dose optimization phase. Participants may be followed for up to five years to track long-term effects and treatment outcomes.